Elias Papatheodorou
Chief Executive Officer at Calliditas Therapeutics Suisse SA
Profile
Elias Papatheodorou is currently the Chief Executive Officer & Director at Calliditas Therapeutics Suisse SA. He is also serving as the Independent Chairman at Memo Therapeutics AG, the Chairman at HepaRegeniX GmbH, and the Director at Tribune Therapeutics AB.
Previously, he held positions such as Chief Executive Officer at Novosom Verwaltungs GmbH from 2004 to 2009, Chief Executive Officer at Genticel SA, Chief Executive Officer & Director at Calliditas Therapeutics France SAS from 2017 to 2021, Chairman at Priaxon AG, Senior VP-Business Development & Operations at MediGene AG, Principal at Philip Morris USA, Inc., and Chief Business Officer at Covagen AG.
Mr. Papatheodorou completed his undergraduate degree at Ithaca College and his graduate degree at Cornell University.
Elias Papatheodorou active positions
| Companies | Position | Start |
|---|---|---|
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Chief Executive Officer | - |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Chairman | - |
HepaRegeniX GmbH
 HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Chairman | 30/03/2022 |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Director/Board Member | - |
Former positions of Elias Papatheodorou
| Companies | Position | End |
|---|---|---|
| GENKYOTEX SA. | Chief Executive Officer | 01/12/2021 |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France. | Chief Executive Officer | - |
Priaxon AG
 Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Chairman | - |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Corporate Officer/Principal | - |
| MEDIGENE AG | Corporate Officer/Principal | - |
Training of Elias Papatheodorou
| Ithaca College | Undergraduate Degree |
| Cornell University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MEDIGENE AG | Health Technology |
| Private companies | 10 |
|---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Philip Morris USA, Inc.
 Philip Morris USA, Inc. TobaccoConsumer Non-Durables Philip Morris USA, Inc. makes and markets tobacco goods. Its products include cigarette non-tobacco, cigarette tobacco and flavor ingredients. The company was founded by Philip Morris in 1847 and is headquartered in Richmond, VA. | Consumer Non-Durables |
Novosom Verwaltungs GmbH
 Novosom Verwaltungs GmbH BiotechnologyHealth Technology Novosom Verwaltungs GmbH provides clinical development services and hospital equipment. It offers its own euqipment and technology to discover new methods of healing and researching on ribonucleic acid. The company was founded by Steffen Panzner in 1999 and is headquartered in Halle, Germany. | Health Technology |
Genticel SA
Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France. | Health Technology |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Commercial Services |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Pharmaceuticals: MajorHealth Technology Calliditas Therapeutics France SAS is a biopharmaceutical company, which engages in the NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The firm’s platform enables the identification of orally available small molecules that selectively inhibit specific NOX enzymes. The company was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France. | Health Technology |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Commercial Services |
Priaxon AG
Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Commercial Services |
- Stock Market
- Insiders
- Elias Papatheodorou